Canada is looking a little left out of things as Health Canada actively reviews the drug Avastin to determine whether the benefits outweigh the risks as a treatment for advanced breast cancer. The U.S. Food and Drug Administration revoked its approval for the drug for patients with metastatic breast cancer Friday because there's no proof that it extends lives or provides enough temporary benefit to outweigh dangerous side effects. Maclean's
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.